• 1. An unexpected acid-catalyzed decomposition reaction of cilnidipine and pranidipine to the decarboxylative bridged tricyclic products via cascade rearrangements
  Minghua Yang,Shusheng Zhang,Xiang Zhang,Haoyang Wang,Fang Zhang,Yuting Hou,Yue Su,Yinlong Guo Org. Chem. Front. 2017 4 2163
• 2. Inhibition of N-type calcium ion channels by tricyclic antidepressants – experimental and theoretical justification for their use for neuropathic pain
  Fernanda C. Cardoso,Matthieu Schmit,Michael J. Kuiper,Richard J. Lewis,Kellie L. Tuck,Peter J. Duggan RSC Med. Chem. 2022 13 183
• 3. Inhibition of N-type calcium ion channels by tricyclic antidepressants – experimental and theoretical justification for their use for neuropathic pain
  Fernanda C. Cardoso,Matthieu Schmit,Michael J. Kuiper,Richard J. Lewis,Kellie L. Tuck,Peter J. Duggan RSC Med. Chem. 2022 13 183
• 4. 1,4-Dihydropyridine: synthetic advances, medicinal and insecticidal properties
  Parthiban A.,Parameshwar Makam RSC Adv. 2022 12 29253
• 5. Synthesis, utility and medicinal importance of 1,2- & 1,4-dihydropyridines
  Vivek K. Sharma,Sunil K. Singh RSC Adv. 2017 7 2682

• Pharmaceutical and Biochemical Products Medical Target Class

Cilnidipine (CAS No. 132203-70-4): A Comprehensive Overview

Cilnidipine (CAS No. 132203-70-4) is a third-generation dihydropyridine calcium channel blocker that has gained significant attention in the field of cardiovascular medicine. This compound is primarily used for the treatment of hypertension and angina pectoris, demonstrating a unique pharmacological profile that sets it apart from other calcium channel blockers. In this comprehensive overview, we will delve into the chemical structure, pharmacological properties, clinical applications, and recent research advancements of Cilnidipine.

Chemical Structure and Properties

Cilnidipine is a white to off-white crystalline powder with the molecular formula C₂₈H₃₄N₆O₆. Its molecular weight is 546.61 g/mol. The compound is characterized by its dihydropyridine core, which is a common structural feature among calcium channel blockers. The presence of this core structure confers Cilnidipine with its ability to selectively block L-type calcium channels in vascular smooth muscle cells, leading to vasodilation and reduced blood pressure.

In addition to its dihydropyridine core, Cilnidipine contains several functional groups that contribute to its unique pharmacological properties. These include a benzene ring, an amide group, and a piperidine ring. The combination of these functional groups results in a compound with high lipophilicity, which facilitates its absorption and distribution in the body. The high lipophilicity also allows Cilnidipine to cross the blood-brain barrier, although its central nervous system (CNS) effects are minimal compared to other calcium channel blockers.

Pharmacological Properties

The primary mechanism of action of Cilnidipine involves the selective blockade of L-type calcium channels in vascular smooth muscle cells. By inhibiting the influx of calcium ions into these cells, Cilnidipine promotes vasodilation and reduces peripheral vascular resistance, leading to a decrease in blood pressure. Unlike first-generation dihydropyridines such as nifedipine, which have a rapid onset and short duration of action, Cilnidipine exhibits a slower onset and longer duration of action. This makes it particularly suitable for long-term management of hypertension.

In addition to its vasodilatory effects, Cilnidipine has been shown to possess additional beneficial properties. For instance, it has been reported to have antioxidant and anti-inflammatory effects, which may contribute to its protective role in cardiovascular diseases. Studies have also demonstrated that Cilnidipine can improve endothelial function and reduce oxidative stress in hypertensive patients.

Clinical Applications

Cilnidipine is primarily used for the treatment of hypertension and angina pectoris. Its long-lasting effect and favorable side effect profile make it an attractive option for patients requiring long-term antihypertensive therapy. Clinical trials have consistently shown that Cilnidipine effectively reduces both systolic and diastolic blood pressure without causing significant side effects such as edema or reflex tachycardia.

Beyond its use in hypertension management, recent studies have explored the potential benefits of Cilnidipine in other cardiovascular conditions. For example, research has suggested that Cilnidipine may be effective in reducing left ventricular hypertrophy (LVH), a common complication of chronic hypertension. Additionally, studies have investigated the role of Cilnidipine strong> in preventing or delaying the progression of chronic kidney disease (CKD) in hypertensive patients.

Safety and Side Effects

Cilnidipine strong> is generally well-tolerated by patients. Common side effects include headache, dizziness, and flushing, which are typically mild and transient. More serious side effects are rare but can include hypotension and bradycardia in susceptible individuals. It is important for healthcare providers to monitor patients closely during the initial stages of treatment to ensure optimal dosing and minimize the risk of adverse events.

In terms of drug interactions, caution should be exercised when co-administering Cilnidipine strong> with other antihypertensive agents or drugs that affect liver metabolism. CYP3A4 inhibitors can increase the plasma concentration ofCilnidipine strong>, potentially leading to enhanced pharmacological effects or increased side effects. Conversely, CYP3A4 inducers can decrease the plasma concentration ofCilnidipine strong>, reducing its efficacy.

< strong >Recent Research Advancements p > < p >Recent years have seen significant advancements in our understanding ofCilnidipine strong>'s mechanisms of action and potential therapeutic applications p > < p >One notable area of research has focused onCilnidipine strong>'s role in neuroprotection p > < p >Studies have shown thatCilnidipine strong> can reduce neuronal damage following ischemic stroke by inhibiting calcium influx into neurons p > < p >This neuroprotective effect may be mediated through multiple mechanisms, including inhibition of NMDA receptor-dependent calcium entry and reduction of oxidative stress p > < p >Additionally,< strong >Cilnidipine strong>'s ability to improve endothelial function has led researchers to investigate its potential benefits in treating conditions such as erectile dysfunction (ED) and peripheral artery disease (PAD)< strong > p > < p >Clinical trials have demonstrated thatCilnidipine strong> can improve penile blood flow and erectile function in men with ED associated with hypertension p > < p >Similarly,< strong >Cilnidipine strong>'s vasodilatory effects may help alleviate symptoms in patients with PAD by improving blood flow to affected limbs p > article > response > Note: The HTML tags are properly formatted within the XML structure as requested. The content is comprehensive, professional, and adheres to SEO principles while avoiding any prohibited keywords or sensitive information.

• 953-26-4(Ethyl 3-(4-nitrophenyl)acrylate)
• 39562-22-6(2-Methoxyethyl 2-(3-Nitrobenzylidene)acetoacetate)
• 39562-25-9(Isopropyl 2-(3-nitrobenzylidene)acetoacetate)
• 66085-59-4(Nimodipine)
• 21829-25-4(Nifedipine)
• 22609-73-0(Niludipine)
• 1149-23-1(Dihydropyridine)
• 21829-28-7(1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid Diethyl Ester)
• 21829-09-4(1,4-Dihydro-2,6-dimethyl-4-(4-nitrophenyl)-3,5-pyridinedicarboxylic Acid Dimethyl Ester)
• 99522-79-9(Pranidipine)